E78.49

Other hyperlipidemia

E78.49 is a specific clinical classification within the ICD-10-CM system designated for forms of hyperlipidemia that are not categorized under more specific codes such as pure hypercholesterolemia (E78.0), pure hyperglyceridemia (E78.1), or mixed hyperlipidemia (E78.2). It encompasses a variety of elevations in plasma lipids, including cholesterol and triglycerides, that may result from complex polygenic factors, rare genetic variants, or secondary metabolic influences. This code is often applied when lab results indicate lipid abnormalities that do not fit the classic phenotype of familial hypercholesterolemia or simple hypertriglyceridemia, or when multiple lipid components are elevated in a manner that requires distinct clinical monitoring and intervention. Management typically involves lifestyle modification, dietary changes, and pharmacotherapy (such as statins, fibrates, or PCSK9 inhibitors) to mitigate the elevated risk of atherosclerotic cardiovascular disease (ASCVD).

Clinical Symptoms

  • Asymptomatic (most common presentation)
  • Xanthomas (lipid deposits in the skin or tendons)
  • Xanthelasma (yellowish deposits around the eyelids)
  • Corneal arcus (white or grey ring around the cornea)
  • Eruptive xanthomas (small, itchy yellow-red bumps on the skin)
  • Abdominal pain (in cases of severe triglyceride elevation/pancreatitis risk)
  • Chest pain or angina (if underlying atherosclerosis is present)
  • Claudication (leg pain during walking due to peripheral artery disease)
  • Transient ischemic attacks (if carotid involvement occurs)

Common Causes

  • Polygenic genetic predisposition
  • Dietary factors (high intake of saturated and trans fats)
  • Secondary metabolic disorders (e.g., diabetes mellitus)
  • Hypothyroidism
  • Chronic kidney disease or nephrotic syndrome
  • Obesity and sedentary lifestyle
  • Medication side effects (e.g., corticosteroids, certain beta-blockers, retinoids)
  • Excessive alcohol consumption

Documentation & Coding Tips

Distinguish between other hyperlipidemia and unspecified hyperlipidemia by identifying specific lipoprotein elevations like IDL or Lp(a).

Example: Patient seen for management of other hyperlipidemia (E78.49). Recent advanced lipid testing confirms significantly elevated Lipoprotein(a) at 150 nmol/L and elevated Intermediate-Density Lipoprotein (IDL). This specifies the other hyperlipidemia diagnosis beyond standard LDL/HDL classifications. Patient remains at high risk for ASCVD and is currently stable on high-intensity Rosuvastatin 40mg.

Billing Focus: The documentation must specify the lipid fraction or subtype (e.g., Lp(a), IDL) that justifies the other hyperlipidemia code rather than the unspecified E78.5 code.

Identify and document the clinical phenotype when standard classifications like pure hypercholesterolemia do not apply.

Example: Clinical evaluation of 48-year-old male with a history of early-onset coronary artery disease and a lipid phenotype demonstrating combined elevations in both LDL and VLDL that do not meet the strict criteria for E78.2. Diagnosed as other hyperlipidemia (E78.49) given the atypical presentation. Ongoing monitoring of lipid panel and carotid intima-media thickness performed.

Billing Focus: Specific phenotypes should be noted in the assessment and plan to support clinical validity.

Explicitly state if the condition is a primary or secondary hyperlipidemia when known.

Example: Patient presents with other hyperlipidemia (E78.49) secondary to poorly controlled Type 2 Diabetes Mellitus. LDL is 145 mg/dL and non-HDL cholesterol is 180 mg/dL. Adjusted insulin regimen and added Ezetimibe 10mg daily to current Statin therapy to address secondary dyslipidemia.

Billing Focus: Linking the lipid disorder to an underlying cause (e.g., diabetes, hypothyroidism) improves diagnostic accuracy and billing specificity.

Document the history of treatment failure or intolerance to standard therapies when managing complex hyperlipidemias.

Example: Other hyperlipidemia (E78.49) management in a patient with a history of statin-associated muscle symptoms. Patient failed Simvastatin and Atorvastatin trials. Currently managing with Bempedoic acid and diet. LDL remains elevated at 130 mg/dL. Considering PCSK9 inhibitor therapy given the refractory nature of the other hyperlipidemia.

Billing Focus: Documentation of treatment failure supports medical necessity for prior authorizations for advanced lipid-lowering therapies.

Use precise terminology for genetic or familial factors if they do not meet the criteria for E78.01.

Example: Patient with family history of premature myocardial infarction presents for other hyperlipidemia (E78.49). Phenotype suggests a familial combined pattern but genetic testing for LDLR is negative. Diagnosis of other hyperlipidemia is maintained based on the presence of multiple elevated lipid subfractions.

Billing Focus: Clarifying the non-familial or non-specific genetic status prevents miscoding to E78.01.

Relevant CPT Codes

Related Diagnoses

Hierarchy